Dear friends,
We are still soliciting bids for our My Pillow DNA project. I’ve got our man from Minnesota on it and he’s busy reaching out to labs. I’m hoping to time the release for the Fox News trial.
If you’re still interested in participating please sign up to be a paid subscriber. I’ll do more of these sorts of things as we get more subscribers. I’m also going to be restricting the comment section to paid subscribers. You’re more than welcome to continue emailing me — please do, in fact — but we have a few trolls out and about and I don’t really want to continue giving them attention.
I believe that there will be a future in which genomic sequencing is so cheap that it’ll be standard for supply chains. You need to know what’s really in your food, what wood our furniture is bad from, and whether or not that fish at the restaurant is really what they say it is.
I can envision a future in which activist short sellers do this sort of research—and then alert authorities to frauds while profiting. Is such a world really so remote? I think not.
I’m currently at work on an investor letter for Traitwell, the genomics company I cofounded. If you’re interested in reading such things, let me know.
I’ll also have a report about the foreign ties of Illumina’s board and leadership to complement the rather excellent work done by Carl Icahn’s team.
Illumina responded thusly about the board: “Illumina’s board of directors acts in the best interests of all of its shareholders and exercises considered and deliberate independent judgement.”
We’ll see that that isn’t exactly true and that there are real national security risks — and #MeToo problems — at Illumina.